Exagen Appoints Ana Hooker to Board of Directors
July 30 2021 - 8:25AM
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing
solutions, is proud to announce the addition of Ms. Ana Hooker as
an additional independent member to its Board of Directors,
effective July 29, 2021.
“We are excited to welcome Ms. Hooker to our
Board of Directors,” said Ron Rocca, Exagen’s President and Chief
Executive Officer. “Ana’s extensive experience in life sciences,
and in particular, clinical laboratories, will play a key role in
Exagen’s continued expansion.”
“I am excited to join the board of such an
innovative company that is having a real impact on patient’s lives
through the differential diagnosis, prognosis and monitoring of
complex autoimmune and autoimmune-related diseases,” said Ms.
Hooker. “Exagen has a world-class laboratory, a robust pipeline and
I look forward to working with the executive leadership team and
board of directors, as the Company continues to execute on its
compelling mission and growth strategy.”
Ana Hooker has served as the Senior Vice
President, Operations of Exact Sciences Corporation, a molecular
diagnostics company, since July 2015. Ms. Hooker joined Exact
Sciences Corporation in March 2013 with a focus on opening a new
clinical laboratory in preparation for the launch of Cologuard.
Prior to joining Exact Sciences Corporation, Ms. Hooker was at ARUP
Laboratories for 15 years. While at ARUP Laboratories, Ms. Hooker
held positions of increasing responsibility, including Group
Manager for the Divisions of Oncology and Genetics, Technical
Supervisor of the University of Utah Hospital Clinical
Laboratories, Vice President, Division Manager for genetics and
Senior Vice President, Division Manager for anatomic pathology,
oncology and genetics. Ms. Hooker currently serves on the boards of
Big Brothers, Big Sisters of Dane County and the Overture Center
for the Arts. Ms. Hooker is also a member of the Latino
Professional Association (LPA), Clinical Laboratory Management
Association (CLMA), Association of Molecular Pathology (AMP), and
the American Society of Clinical Laboratory Science (ASCLS). Ms.
Hooker earned a Bachelor of Science from Kansas State University, a
medical technologist degree from Hays Pathology Laboratories, and
an M.B.A. from Westminster College.
About Exagen
Exagen is dedicated to transforming the care
continuum for patients suffering from debilitating and chronic
autoimmune diseases by enabling timely differential diagnosis and
optimizing therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable providers to improve care for patients
through the differential diagnosis, prognosis and monitoring of
complex autoimmune and autoimmune-related diseases, including
rheumatoid arthritis and lupus. For more information, please visit
www.Exagen.com.
Forward Looking Statements
Exagen cautions you that statements in this
press release that are not a description of historical facts are
forward-looking statements. These statements are based on the
Exagen's current beliefs and expectations. Such forward-looking
statements include, but are not limited to, statements regarding
Exagen’s goals and strategies, the potential utility and
effectiveness of Exagen’s services and testing solutions, Exagen’s
potential growth and expansion and management’s views and
expectations of the same. The inclusion of forward-looking
statements should not be regarded as a representation by Exagen
that any of its plans will be achieved. Actual results may differ
from those set forth in this press release due to the risks and
uncertainties inherent in Exagen’s business, including, without
limitation: the COVID-19 pandemic may continue to adversely affect
our business, financial condition and results of operations,
including as a result of shutdowns of our facilities and operations
as well as those of our suppliers and courier services, impeding
patient movement and interruptions to healthcare services causing a
decrease in test volumes, disruptions to the supply chain of
material needed for our tests, our sales and commercialization
activities and our ability to receive specimens and perform or
deliver the results from our tests, delays in reimbursement and
coverage decisions from Medicare and third-party payors and in
interactions with regulatory authorities, and delays in ongoing and
planned clinical trials involving our tests; the company’s
commercial success depends upon attaining and maintaining
significant market acceptance of its testing products and promoted
therapeutics among rheumatologists, patients, third-party payers
and others in the medical community; the company’s ability to
successfully execute on its business strategies; third party payers
not providing coverage and adequate reimbursement for the company’s
testing products or promoted therapeutics; the company’s ability to
obtain and maintain intellectual property protection for its
testing products; regulatory developments affecting the company’s
business; and other risks described in the company’s prior press
releases and Exagen’s filings with the Securities and Exchange
Commission (SEC), including under the heading “Risk Factors” in the
company’s Annual Report on Form 10-K for the year ended December
31, 2020 on and any subsequent filings with the SEC. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and Exagen
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date
hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, which is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
CONTACTS:
Investor RelationsExagen
Inc.Ryan Douglasrdouglas@exagen.com760.560.1525
CompanyExagen Inc.Kamal Adawi,
Chief Financial Officerkadawi@exagen.com760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jul 2023 to Jul 2024